Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration

International Journal of Cancer

Volumn 121, Issue 2, 2007, Pages 276-283

  Eckerich, Carmen ^a   Zapf, Svenja ^a   Fillbrandt, Regina ^a   Loges, Sonja ^a   Westphal, Manfred ^a   Lamszus, Katrin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Glioblastoma; Hepatocyte growth factor; Hypoxia; Invasion; Met

Indexed keywords

COMPLEMENTARY DNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P53; RNA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ARTICLE; CELL MIGRATION; CELL TYPE; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; GLIOBLASTOMA; HEPATOCYTE GROWTH FACTOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 34250340883     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22679     Document Type: Article

References (52)

1. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? trends Mol Med 2005;11:284-92.
2. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005;15:49-51.
3. Schmidt L, Dull FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
4. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376:768-71.
5. Takayama H, LaRoehelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997;94:701-6.
6. Lamszus K, Laterra J, Westphal M, Rosen EM. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 1999;17:517-30.
7. Abounader R, Laterra J. Scatter factor/hepalocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncol 2005;7:436-51.
8. Laterra J, Nam M, Rosen E, Rao JS, Lamszus K, Goldberg ID, Johnston P. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 1997;76:565-77.
9. Brockmann MA, Papadimitriou A, Brandt M, Fillbrandt R, Westphal M, Lamszus K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 2003;9:4578-85.
10. Brockmann MA, Ulbrichl U, Gruner K, Fillbrandt R, Westphal M, Lamszus K. Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 2003;52:1391-9.
11. Acker T, Plate KH. Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. Cancer Treat Res 2004; 117:219-48.
12. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. 2001;28:36-41.
13. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
14. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61.
15. Hayashi M, Sakata M, Takeda T, Tahara M, Yamnmoto T, Okamoto Y, Minekawa R, Isobe A, Ohmichi M, Tasaka K, Murata Y. Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1α is involved in trophoblast invasion under low-oxygen tension. Endocrinology 2005;146:4682-9.
16. Hara S, Nakashiro K, Klosek SK, Ishikawa T, Shintani S, Hamakawa H. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1α in human salivary gland cancer cells. Oral Oncol 2006;42:593-8.
17. Abounader R, Ranganathan S, Kim BY, Nichols C, Laterra J. Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. J Neurochem 2001;76:1497-508.
18. Tamaki M, McDonald W, Amberger VR, Moore E, Del Maestro RF. Implantation of C6 astrocytoma spheroid into collagen type I gels: invasive, proliferative, and enzymatic characterizations. J Neurosurg 1997;87:602-9.
19. Plasswilm L, Tannapfel A, Cordes N, Demir R, Hoper K, Bauer J, Hoper J. Hypoxia-induced tumour cell migration in an in vivo chicken model. Pathobiology 2000;68:99-105.
20. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B, Van Meir EG. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004;64:920-7.
21. Westphal M, Hansel M, Hamel W, Kunzmann R, Holzel F. Karyotype analyses of 20 human glioma cell lines. Acta Neurochir (Wien) 1994;126:17-26.
22. Wessel D, Flugge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984;138:141-3.
23. Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P, Westphal M. p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer 1993;55:982-7.
24. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van Meir EG. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-79.
25. Kim EL, Yoshizato K, Kluwe L, Meissner H, Warnecke G, Zapf S, Westphal M, Deppert W, Giese A. Comparative assessment of the functional p53 status in glioma cells. Anticancer Res 2005;25:213-24.
26. Pedersen PH, Ness GO, Engebraaten O, Bjerkvig R, Lillehaug JR, Laerum OD. Heterogeneous response to the growth factors [EGF, PDGF (bb), TGF-alpha, bFGF, IL-2] on glioma spheroid growth, migration and invasion. Int J Cancer 1994;56:255-61.
27. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-52.
28. Yuan Y, Hilliard G, Ferguson T, Millhorn DE. Cobalt inhibits the interaction between hypoxia-inducible factor-α and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-α. J Biol Chem 2003;278:15911-16.
29. Seol DW, Chen Q, Smith ML, Zarnegar R. Regulation of the c-met protooncogene promoter by p53. J Biol Chem 1999;274:3565-72.
30. Moghul A, Lin L, Beedle A, Kanbour-Shakir A, DeFrances MC, Liu Y, Zarnegar R. Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript. Oncogene 1994;9:2045-52.
31. de Juan C, Sanchez A, Nakamura T, Fabregat I, Benito M. Hepatocyte growth factor up-regulates met expression in rat fetal hepatocytes in primary culture. Biochem Biophys Res Commun 1994;204:1364-70.
32. Zhang X, Yang J, Li Y, Liu Y. Both Sp1 and Smad participate in mediating TGF-β1-induced HGF receptor expression in renal epithelial cells. Am J Physiol Renal Physiol 2005;288:F16-26.
33. Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, Lamszus K. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999;84:10-18.
34. Fischer U, Muller HW, Sattler HP, Feiden K, Zang KD, Meese E. Amplification of the MET gene in glioma. Genes Chromosomes Cancer 1995;12:63-5.
35. Liu L, Ichimura K, Pettersson EH, Collins VP. Chromosome 7 rearrangements in glioblastomas; loci adjacent to EGFR are independently amplified. J Neuropathol Exp Neurol 1998;57:1138-45.
36. Reifenberger G, Collins VP. Pathology and molecular genetics of astrocytic gliomas. J Mol Med 2004;82:656-70.
37. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992;1:45-9.
38. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61:6624-8.
39. Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2. epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 2005;11:4934-40.
40. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2:306-14.
41. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS, Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003;4:133-46.
42. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to antiangiogenic glioma therapy. Acta Neurochir Suppl 2003;88:169-77.
43. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003;63:1138-43.
44. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425:307-11.
45. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 Nat Med 2004;10:858-64.
46. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit MD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001;61:39-44.
47. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
48. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
49. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000; 88:2606-18.
50. Rosen EM, Laterra J, Joseph A, Jin L, Fuchs A, Way D, Witte M, Weinand M, Goldberg ID. Scatter factor expression and regulation in human glial tumors. Int J Cancer 1996;67:248-55.
51. Koochekpour S, Jeffers M, Rufong S, Taylor G, Klineberg E, Hudson EA, Resau JH, Vande Woude GF. Met and hepatocyte growth factor/ scatter factor expression in human gliomas. Cancer Res 1997;57: 5391-8.
52. Hirose Y, Kojima M, Sagoh M, Murakami H, Yoshida K, Shimazaki K, Kawase T. Immunohistochemical examination of c-Met protein expression in astrocytic tumors. Acta Neuropathol (Berl) 1998;95: 345-51.